TRENDING KEYWORDS
Pfizer (PFE, $56.66)-Biontech get FDA nod on booster shots for 12-15 year olds
Pfizer Inc. and BioNTech got approval from The Food and Drug Administration (FDA) for authorizing Covid booster shots in children aged 12 to 15. This is an emergency use authorization, amid omicron variant spread.
The FDA also narrowed the time for administration of a booster dose from at least six months to at least five months following completion of the primary series for people 12 and older.
The authority, which had already approved the vaccine use for people 16 years and older, has expanded authorization of the vaccine to include a third dose at least 28 days following the second dose for people 5 through 11 who are immunocompromised.
PFE's RSI Indicator climbs out of oversold territory
The RSI Indicator for PFE moved out of oversold territory on April 25, 2022. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 31 similar instances when the indicator left oversold territory. In 21 of the 31 cases the stock moved higher. This puts the odds of a move higher at 68%.
Current price $50.49 crossed the resistance line at $49.58 and is trading between $53.84 resistance and $49.58 resistance lines. Throughout the month of 04/13/22 - 05/16/22, the price experienced a -4% Downtrend, while the week of 05/09/22 - 05/16/22 shows a +5% Uptrend.
The Momentum Indicator moved above the 0 level on May 12, 2022. You may want to consider a long position or call options on PFE as a result. In 44 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 53%.
The Moving Average Convergence Divergence (MACD) for PFE just turned positive on May 11, 2022. Looking at past instances where PFE's MACD turned positive, the stock continued to rise in 24 of 46 cases over the following month. The odds of a continued upward trend are 52%.
Following a +2.73% 3-day Advance, the price is estimated to grow further. Considering data from situations where PFE advanced for three days, in 166 of 315 cases, the price rose further within the following month. The odds of a continued upward trend are 53%.
The Aroon Indicator entered an Uptrend today. In 123 of 333 cases where PFE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 37%.
The Stochastic Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
PFE moved below its 50-day Moving Average on April 19, 2022 date and that indicates a change from an upward trend to a downward trend.
The 10-day Moving Average for PFE crossed bearishly below the 50-day moving average on April 26, 2022. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 53%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PFE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 48%.
PFE broke above its upper Bollinger Band on May 12, 2022. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Tickeron has a positive outlook on this ticker and predicts a further increase by more than 4.00% within the next month with a likelihood of 62%. During the last month, the daily ratio of advancing to declining volumes was 1 to 1.01.
The Tickeron Valuation Rating of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.398) is normal, around the industry mean (6.843). P/E Ratio (11.249) is within average values for comparable stocks, (85.171). Projected Growth (PEG Ratio) (1.110) is also within normal values, averaging (3.164). Dividend Yield (0.032) settles around the average of (0.026) among similar stocks. P/S Ratio (3.096) is also within normal values, averaging (3.807).
The Tickeron Profit vs. Risk Rating rating for this company is 11 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 62, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating steady price growth. PFE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 74 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 74 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
The average market capitalization across the Pharmaceuticals: Major Industry is 77.7B. The market cap for tickers in the group ranges from 226K to 465.4B. JNJ holds the highest valuation in this group at 465.4B. The lowest valued company is NEWG at 226K.
The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was 1.03%. For the same Industry, the average monthly price growth was -4.83%, and the average quarterly price growth was -7.85%. GIFOF experienced the highest price growth at 17.34%, while DCHPF experienced the biggest fall at -28.83%.
- 4/20/22 8:58 AM: Pfizer (PFE, $50.18) was a top loser this week, declining -5.52%
- 4/12/22 7:11 AM: Pfizer (PFE, $53.93) was a top weekly gainer, with a +5.87% jump
- 3/15/22 5:19 AM: Pfizer (PFE, $52.25) was a top weekly gainer, with a +8.9% jump
The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was -5.23%. For the same stocks of the Industry, the average monthly volume growth was 12.33% and the average quarterly volume growth was -2.15%
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Stocks in the group have a Negative Outlook today, backed by the MA200MA50 Indicator. Tickeron has a negative outlook on this group and predicts a further decline by more than 4.00% within the next month with a likelihood of 48%. During the last month, the daily ratio of advancing to declining volumes was 1 to 1.13.
27 stocks in the group of tickers confirmed the negative outlook based on the Declines indicator with average odds of 54%.
The most notable companies in this group are Johnson & Johnson (NYSE:JNJ), Pfizer (NYSE:PFE), Eli Lilly & Co (NYSE:LLY), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), AstraZeneca PLC (NASDAQ:AZN), Bristol-Myers Squibb Co (NYSE:BMY), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Biogen (NASDAQ:BIIB).
The average market capitalization across the group is 97.5B. The market cap for tickers in the group ranges from 23.6M to 465.4B. JNJ holds the highest valuation in this group at 465.4B. The lowest valued company is CRXT at 23.6M.
- 2/26/22 6:56 AM: Johnson & Johnson (JNJ, $166), market cap jumped by $20.7B
The average weekly price growth across all stocks in the group was 2.28%. For the same group, the average monthly price growth was -5.06%, and the average quarterly price growth was -4.92%. GRFS experienced the highest price growth at 11.07%, while RHHBY experienced the biggest fall at -8.83%.
- 5/12/22 5:38 AM: GlaxoSmithKline (GSK, $42.53) was a top loser this week, declining -5.82%
- 5/10/22 5:36 AM: Mayne Pharma Group (MAYNF, $0.19) was a top loser this week, declining -9.52%. Expect a Downtrend reversal
- 5/7/22 5:28 AM: Biogen (BIIB, $193.61) was a top loser this week, declining -6.67%
The average weekly volume growth across all stocks in the group was -29.89%. For the same stocks of the group, the average monthly volume growth was 59.4% and the average quarterly volume growth was 92.07%
- 5/5/22 4:51 AM: The volume for Clarus Therapeutics Holdings stock increased for two consecutive days, resulting in a record-breaking daily growth of 192% of the 65-Day Volume Moving Average
- 5/5/22 4:51 AM: The volume for Horizon Therapeutics Public stock increased for one day, resulting in a record-breaking daily growth of 246% of the 65-Day Volume Moving Average
- 4/22/22 6:34 AM: The volume for Clarus Therapeutics Holdings stock increased for one day, resulting in a record-breaking daily growth of 1,022% of the 65-Day Volume Moving Average
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Latest blogs by Abhoy Sarkar
Top Blogs
